Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-2
2020-000557-27Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of navitoclax and ruxolitinib in myelofibrosis (MF) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Spleen volume response rate at Week 24. Started Jul 2020; status: terminated.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-000557-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000557-27.